THE WOODLANDS, Texas, Dec. 19, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® (Nasdaq: RPRX ) today announced it has added Michael Suesserman to the Company's Board of Directors.
Michael Suesserman is currently Managing Director, Cello Health Consulting, providing advisory services to the global life sciences industry. Mike brings over two decades of experience in launching, building, and developing pharmaceutical marketing platforms, including those for the megabrands Lipitor and Viagra.
Mike's breadth of experience in commercializing pharmaceuticals spans the entire product lifecycle, including portfolio prioritization, product development, US and Global product management, life-cycle extension as well as reimbursement and market access. He spent 18 years at Pfizer, in roles of increasing responsibility. He was the US and then Global Team Leader for Lipitor, was responsible for the global urology franchise and also held the position of VP, Managed Markets Group in the US.
In addition to overall commercial expertise, Mike has extensive experience in a number of therapeutic areas, particularly urology. He was responsible for the commercial development of Pfizer's Sexual Health franchise strategy, re-positioning and re-launching Viagra in the face of the global introductions of Cialis and Levitra, and creating access and formulary placement for Detrol LA in the US.
Mike holds an MBA from Kelley School of Business at Indiana University and earned his Bachelor's degree in Economics from Clark University.
Joseph Podolski, President and CEO of Repros commented, "We are fortunate to have Mike join the Repros Board of Directors. His unique skill set provides Repros with important sales and marketing insight to help us develop our strategy to maximize shareholder returns for our lead product Androxal." He further noted, "Assuming Androxal attains US FDA approval, we believe it has the potential of the 'megabrands' Mike has been intimately associated with, driving these drugs to commercial success."
About Repros Therapeutics Inc.
Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.
Any statements made by the Company that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including the ability to have success in the clinical development of its technologies, the reliability of interim results to predict final study outcomes, the ability to protect its intellectual property rights and such other risks which are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov . Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please visit the Company's website at http://www.reprosrx.com .
Investor Relations: Thomas Hoffmann The Trout Group (646) 378-2931
